Identification of LS is typical through cancer patients, and tumor-based triage tests (immunohistochemistry [IHC] for MMR protein loss, MSI testing or MLH1 promoter methylation testing) are the means which identify the cases needing to undergo germline testing for identification of the MMR gene pathogenic variant (3, 4). Here, MRC1 is linked to neoplasm.